local · RTHK

Hong Kong speeds drug approval push after ICH entry

about 13 hours ago3 MIN
Hong Kong speeds drug approval push after ICH entry

Summary

Hong Kong has formally joined the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, or ICH, as a regulatory authority member after the organisation approved the move at its assembly in the Czech Republic on November 17. The Medical and Health Bureau said the new status recognises Hong Kong's drug research and regulatory standards internationally and should help develop the city's capacity and mechanism for first-tier approval of innovative medicines. Officials also linked the membership to the launch next month of the Hong Kong Centre for Medical Products Regulation, which is intended to build an independent drug evaluation and approval system. The Department of Health said the first phase of the first-tier approval mechanism has already received five expressions of interest from mainland and overseas drugmakers and is now reviewing the data.

Key Points

  • The ICH assembly in the Czech Republic approved Hong Kong's membership on November 17, with the Pharmacy and Poisons Board representing the city as its 20th regulatory authority member.
  • Secretary for Health Lo Chung-mau said Hong Kong moved from ICH observer status on October 31, 2023 to full regulatory membership within three years, faster than the earlier estimate of eight to 10 years.
  • Lo said the government will set up the Centre for Medical Products Regulation next month to build independent drug review and approval capacity and support Hong Kong's medical innovation hub ambitions.
  • Director of Health Ronald Lam Man-kin said the new centre will form a professional review team under ICH technical requirements, improve innovative drug assessment efficiency and send experts to help draft and revise ICH guidelines.
  • Assistant Director of Health Chan Ling-fung said the first phase of first-tier approval has received five expressions of interest, covering three formulation changes, one new indication and one packaging-related change.

Why It Matters

For patients and the life sciences sector, the practical issue is whether Hong Kong can move more quickly from relying on overseas reference approvals toward handling more drug reviews on its own. Officials argue that holding both ICH and PIC/S membership should strengthen the credibility of the coming regulator and give Hong Kong a bigger role in shaping international pharmaceutical standards, not just following them.

READ IT IN THE APP

Download on the App Store